Orlando, Fla.—Morbidly obese patients experience significantly faster recovery from rocuronium- or vecuronium-induced neuromuscular blockade when sugammadex (Bridion, Merck) dosing uses actual body weight instead of ideal body weight, a new study has concluded. The additional dosing also did not increase safety concerns, although some clinicians questioned whether it was worth the extra cost.
“The FDA approved sugammadex in December 2015,” said W. Joseph Herring, MD, PhD, the